Capricor Therapeutics Investors Alert: Join the Class Action
Capricor Therapeutics Class Action Lawsuit Overview
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is currently involved in a significant class action lawsuit that has drawn attention from investors. This legal action aims to protect the rights of shareholders who might have experienced financial losses due to certain misleading information released by the company regarding its lead cell therapy candidate, deramiocel.
Understanding the Lawsuit and Implications
The class action lawsuit is designed to secure compensation for investors who were adversely impacted by allegations of securities fraud that occurred from October 9, 2024, to July 10, 2025. If you are a shareholder within this period, understanding the details of the allegations can be vital to your next steps.
Key Allegations
This lawsuit stems from claims that Capricor's management provided investors with overly optimistic statements regarding deramiocel, particularly regarding its FDA approval process for its Biologics License Application (BLA). The critical issue arose when the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) because the company failed to provide adequate evidence of the drug's effectiveness, thus impacting stock prices significantly.
Consequences of the FDA Response
On July 11, 2025, after the announcement from the FDA, the stock price fell sharply from $11.40 to $7.64. This drop reflects the potential financial losses that shareholders could be facing, making the class action crucial for affected individuals seeking justice and compensation.
Joining the Class Action as a Lead Plaintiff
If you have suffered losses during the determined period, you have the opportunity to become a lead plaintiff in this class action lawsuit by filing your request before the deadline of September 15, 2025. Becoming a lead plaintiff may enhance your standing in the case, although it is not a requirement to recover losses.
No Costs Involved
It's important to note that if you join the class action as a member, there may be no out-of-pocket expenses incurred. Participation does not obligate you to pay fees upfront, making it accessible for investors who wish to reclaim their losses without financial risk.
Why Choose Levi & Korsinsky?
The legal team at Levi & Korsinsky, LLP, has an established history, having secured substantial recoveries for aggrieved shareholders over the past two decades. Their expertise in handling complex securities cases positions them as trusted advocates for investors. For consecutive years, they have ranked high in offerings of reputable securities litigation firms.
Contact Information for Interested Investors
Investors looking to connect with the team at Levi & Korsinsky can do so via email or phone. Joseph E. Levi, Esq. is a contact person for inquiries related to the lawsuit. They are located at 33 Whitehall Street, 17th Floor, New York, NY 10004. For more information or to discuss your potential involvement, reach out at (212) 363-7500.
Frequently Asked Questions
What is the class action lawsuit about?
The lawsuit aims to recover losses for investors who suffered from misleading statements made by Capricor regarding its drug development process.
Who qualifies to join the class action?
Any investor who held shares of Capricor between October 9, 2024, and July 10, 2025, and experienced a loss may qualify to participate.
What do I need to do to become a lead plaintiff?
If you wish to become a lead plaintiff, you must submit your request by the deadline of September 15, 2025.
Are there any costs to join the class action?
No, class members may participate without any upfront fees or costs required.
How can I contact Levi & Korsinsky for more information?
You can reach out to Joseph E. Levi, Esq. via phone at (212) 363-7500 or visit their office at 33 Whitehall Street in New York.
About The Author
Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
